U.S. Markets open in 16 mins
  • S&P Futures

    4,197.25
    -25.00 (-0.59%)
     
  • Dow Futures

    33,530.00
    -275.00 (-0.81%)
     
  • Nasdaq Futures

    14,110.25
    -55.25 (-0.39%)
     
  • Russell 2000 Futures

    2,259.60
    -24.90 (-1.09%)
     
  • Crude Oil

    70.64
    -0.40 (-0.56%)
     
  • Gold

    1,779.00
    +4.20 (+0.24%)
     
  • Silver

    26.16
    +0.30 (+1.16%)
     
  • EUR/USD

    1.1882
    -0.0028 (-0.2376%)
     
  • 10-Yr Bond

    1.5040
    -0.0070 (-0.46%)
     
  • Vix

    19.62
    +1.47 (+8.10%)
     
  • GBP/USD

    1.3861
    -0.0063 (-0.4546%)
     
  • USD/JPY

    110.2940
    +0.0630 (+0.0571%)
     
  • BTC-USD

    37,303.27
    -1,385.96 (-3.58%)
     
  • CMC Crypto 200

    924.01
    -45.86 (-4.73%)
     
  • FTSE 100

    7,045.48
    -107.95 (-1.51%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Seres Therapeutics, Inc., (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.

A live audio webcast of the panel will be available under the "Investors and News" section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and plans to initiate a clinical program with SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005069/en/

Contacts

PR Contact
Kristin Ainsworth
kainsworth@serestherapeutics.com

IR Contact
Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com